CTOs on the Move

New Jersey Precision Technology

www.njpt.com

 
New Jersey Precision Technology is a Mountainside, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.njpt.com
  • 1081 Bristol Rd
    Mountainside, NJ USA 07092
  • Phone: 908.232.8847

Executives

Name Title Contact Details

Similar Companies

Finishing Touch Salon

Finishing Touch Salon is a Waterbury, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Segra

Our solution: Segra leverages expertise in biochemistry, botany, plant tissue culture, genetic testing, and production under strict regulatory environments to bring end-to-end solutions for product production and sale in the medical Cannabis space.

PT Development LLC.

PT Development (PTD) is a Louisville-based operational management firm that specializes in providing operational efficiencies such as accounting, customer service, marketing, compliance, and human resource services to privately held physical therapy practices.   Founded by Dr. Larry Benz in 1994, PTD’s primary goal is to help our clients achieve clinical excellence through aligning business strategies, streamlining processes, and building equity through quality customer service.

Prescos

Prescos is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sengenics

Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.